CIK 0001658551
- Non-accelerated filer
- Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464600503
- Phone
- +1 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Open-market sale 10% owner sold 100,000 shares at an average $35.78 ($3,578,103)
- 5 Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale Chief Medical Officer sold 2,034 shares at an average $36.30 ($73,831)
- 4 Open-market sale Co-Chief Executive Officer sold 5,968 shares at an average $36.30 ($216,629)
- 4 Open-market sale Chief Financial Officer sold 2,658 shares at an average $36.30 ($96,481)
- 4 Open-market sale Chief Commercial Officer sold 2,403 shares at an average $36.30 ($87,225)
- 4 Open-market sale Co-Chief Executive Officer sold 5,968 shares at an average $36.30 ($216,629)
- 4 Option exercise Chief Financial Officer acquired 5,000 shares (option exercise)
- 4 Open-market sale 10% owner sold 1,400,000 shares at an average $29.80 ($41,719,639)
- 4 Open-market sale 10% owner sold 60,609 shares at an average $20.70 ($1,254,642)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise Co-Chief Executive Officer acquired 334,520 shares (option exercise)
- 4 Option exercise Co-Chief Executive Officer acquired 334,520 shares (option exercise)
- 4 Conversion 10% owner acquired 5,955,889 shares (conversion)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
Page 9 of 11 · 207 filings